Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Very Bullish +85

Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now

📈 Cardinal Health delivered strong fiscal Q3 results, driven by robust pharmaceutical distribution and accelerating specialty services.

💼 The company holds a Zacks Rank #2 (Buy) status and is positioned for continued growth via its expanding specialty portfolio.

📉 Shares have lost 2.5% year-to-date compared to the industry’s 9.3% decline, while the S&P 500 rose 8.1% in the same period.

💰 Cardinal Health has a market capitalization of $46.93 billion and projects 15.7% growth over the next five years.

🎯 Earnings have surpassed the Zacks Consensus Estimate for four consecutive quarters with an average surprise of 13.21%.

🚀 Pharmaceutical and Specialty Solutions segment revenue grew 11% in Q3 fiscal 2026, fueled by strong demand across specialty, generics, and consumer health.

⚡ Specialty revenues expanded over 20%, with oncology growing more than 30%, while management expects specialty revenues to exceed $50 billion in fiscal 2026.

🌐 At-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics saw revenues surge 31% to $1.7 billion in the fiscal third quarter.

🩺 Theranostics growth exceeded 30%, while Advanced Diabetes Supply added nearly 500,000 patients through continued integration progress.

💵 The company generated $1.7 billion in adjusted free cash flow in the third quarter and raised fiscal 2026 guidance to $3.3-$3.7 billion.

🔄 Cardinal Health repurchased $1 billion worth of shares year-to-date, reducing leverage to 3.0x within its target range.

📉 The Inflation Reduction Act (IRA) pricing adjustments reduced reported revenue growth by approximately 6 percentage points in the fiscal third quarter.

🏭 Global Medical Products and Distribution (“GMPD”) segment revenues were flat year-over-year due to tariff-related headwinds and lower distribution volumes.

🛠️ Management continues to invest in automation, technology upgrades, and supply-chain improvements to maintain record-high service levels.

📊 The Zacks Consensus Estimate for 2026 EPS improved 3.9% over the past 30 days to $10.72.

Bullish Signals
  • Cardinal Health delivered strong fiscal third-quarter results with revenue growth in its Pharmaceutical and Specialty Solutions segment of 11%, including specialty revenues growing over 20%.
  • Oncology growth within the pharmaceutical segment expanded by more than 30%, while theranostics grew by over 30% in other businesses like Nuclear and Precision Health Solutions (NPHS).
  • The company generated $1.7 billion in adjusted free cash flow during the third quarter and has raised its fiscal 2026 free cash flow guidance to $3.3-$3.7 billion.
  • Cardinal Health repurchased $1 billion worth of shares year to date, exceeding its baseline target while reducing leverage to 3.0x, which is comfortably within its target range.
  • Management increased fiscal 2026 free cash flow guidance to $3.3-$3.7 billion, reflecting confidence in future performance and continued improvement in the business.
  • Earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 13.21%.
  • The company's shares have lost only 2.5% so far this year compared to the industry's 9.3% decline, demonstrating relative strength in a challenging environment.
  • Specialty revenues are expected to exceed $50 billion in fiscal 2026, supported by MSO expansion, biopharma solutions, and the Solaris integration.
  • The Zacks Consensus Estimate for earnings per share (EPS) has improved 3.9% to $10.72 over the past 30 days, indicating an improving estimate revision trend.
Risk Factors
  • Cardinal Health's shares have lost 2.5% year-to-date, significantly underperforming the S&P 500 which increased 8.1% during the same period.
  • The Global Medical Products and Distribution (GMPD) segment revenues remained flat year over year while profit declined to $25 million due to tariff-related headwinds and lower distribution volumes.
  • Inflation Reduction Act (IRA)-related WAC pricing adjustments reduced revenue growth by approximately 6 percentage points in the fiscal third quarter, offsetting positive GLP-1 contributions.
  • GMPD profitability remains vulnerable to external pressures such as tariffs, fuel costs, and commodity inflation, which could delay margin recovery in this segment.
  • Lower branded drug prices can suppress reported top-line growth due to IRA pricing changes, even if contract economics remain protected through fee renegotiations.
  • The shift from branded drugs to generics following loss-of-exclusivity events can limit revenue visibility despite being favorable for profitability.
Full Analysis
Cardinal Health (CAH) shares have outperformed the broader market and industry peers, losing only 2.5% year-to-date compared to a 9.3% decline in the healthcare industry and an 8.1% rise in the S&P 500. The company reported strong fiscal third-quarter results driven by robust demand in pharmaceutical distribution and accelerating specialty services, positioning it for continued growth through portfolio expansion. Analysts assign the stock a Zacks Rank #2 (Buy), noting its market capitalization of $46.93 billion and projecting 15.7% revenue growth over the next five years. Cardinal Health consistently surpassed earnings estimates in each of the trailing four quarters with an average surprise of 13.21%. Core earnings momentum is driven by the Pharmaceutical and Specialty Solutions segment, which delivered 11% revenue growth and 18% profit growth in the third quarter of fiscal 2026. Specialty revenues grew more than 20%, with oncology expanding over 30%, bolstering long-term earnings potential while reducing reliance on low-margin traditional drug distribution. Management expects specialty revenues to exceed $50 billion in fiscal 2026, supported by MSO expansion, biopharma solutions, and the Solaris integration. Additionally, growth businesses such as At-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics contributed significantly, with combined revenues surging 31% to $1.7 billion and profit rising 34% to $179 million. Financial strength is underscored by robust cash flow generation, which saw adjusted free cash flow reach $1.7 billion in the third quarter, prompting a raised full-year guidance of $3.3-$3.7 billion for fiscal 2026. The company has repurchased $1 billion worth of shares year-to-date while reducing leverage to 3.0x, maintaining flexibility for specialty expansion and disciplined acquisitions. Operational execution is improving through automation, technology upgrades, and supply-chain investments that maintained record-high service levels despite winter storms and global disruptions. These initiatives aim to enhance scalability and margin resilience across the GMPD segment. Despite these strengths, investors should note specific headwinds affecting revenue visibility. Inflation Reduction Act (IRA) pricing adjustments reduced reported pharmaceutical revenue growth by approximately 6 percentage points in the third quarter, effectively offsetting gains from GLP-1 drugs. The GMPD segment faces execution risks with flat year-over-year revenues and a profit decline to $25 million due to tariff headwinds, lower distribution volumes, and softer demand for respiratory and laboratory products. While estimate revisions have improved by 3.9% over the past 30 days to an earnings per share consensus of $10.72 for fiscal 2026, structural shifts like loss-of-exclusivity events may continue to limit top-line growth visibility even as profitability improves.